Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FRIGITRONICS AND MYLAN PACE AUGUST HEALTH CARE STOCK REBOUND; 37 ISSUES UP

Executive Summary

FRIGITRONICS AND MYLAN PACE AUGUST HEALTH CARE STOCK REBOUND; 37 ISSUES UP Frigitronics (up 10 to 33-7/8) and generic mfr. Mylan (up 7-3/4 to 27-5/8) paced rebounding pharmaceutical and health care issues during August. Following a July during which declining issues outnumbered advances 30 to 12, in August 37 stocks moved ahead, 31 a point or more, while only 5 declined and one remanded unchanged. Frigitronics moved up during the month that Cooper Labs disclosed that it has increased its investment in the firm to over 11% (350,000 shares). The 10-point gain boosted Frigitronics valuation by 41.2% to over $107 mil. With the continued favorable prospects for an ANDA bill -- the measure passed the Senate Aug. 10 -- generic drug stocks performed strongly. In addition to recent strong sales and earnings, Mylan is viewed as an initial prime beneficiary of the legislation with a generic version of Dyazide. After splitting 3-for-2 on Aug. 1, the stock advanced to close to its pre-split level of 29-3/4. Par's valuation climbed 44.7% to $70.4 mil. on the strength of its recent launch of generic indomethacin. The firm posted more than $1 mil. in first day sales of the product. The initial indomethacin sales nearly equaled the firm's monthly volume over the previous quarter. Also performing strongly were LyphoMed (up 3 to 14-7/8, Zenith [up] 2 to 16-1/2), and contract mfr. KV (up 1-1/2 to 8). Biotechnology stocks recouped some of the losses incurred in July. Leading the group's advance were Hybritech (up 3-1/4 to 14-1/4), Viratek (up 2-1/4 to 14-3/4), and Enzo Biochem [up] 2 to 14-1/4). Biogen, which signed a joint development agreement with SmithKline Beckman for tissue plasminogen activator and received a product patent for alpha interferon from the European Patent Office added 1-1/4 to 8. Also performing strongly were Cetus, which gained 1-7/8 to 11-3/8, Immunex (up 1-1/4 to 5-5/8) and Genentech (up 1 to 33-1/4). Glaxo (up 1-1/2 to 12-1/2) received a bumper crop of good regulatory news during the month. FDA gave final marketing approval to the beta blocker labetalol, which is co-marketed with Schering-Plough, and cleared the bronchodilator Ventolin for use in a new indication, exercise-induced bronchospasm. The agency's Gastrointestinal Drugs Advisory Cmte. also recommended that Zantac be approved for use in a once-a-day regimen. The Diversified Component's decline was due to heavily weighted Beecham, which slipped 5/8 to 4.5. Only one other Diversified issue, Chattem, lost ground in August. Chattem was off 1/2 to 15-3/4. All eight whslrs. moved up a point or more, with Spectro (up 3-3/4 to 26-5/8) posting the largest advance. Also gaining at least three on the month were S-P Drug (up 3-1/4 to 14), DurrFillauer (up 3-1/8 to 14-1/4) and Bindley Western (up 3 to 21). FoxMeyer, which picked up its fourth whslr. in 12 months, Yahr-Lange, and reported net income and volume gains for the first quarter ended June 30, added 1 to 24-1/2.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel